Dr. Lizee is currently a Professor in the Departments of Melanoma Medical Oncology and Immunology at M.D. Anderson Cancer Center in Houston, Texas, where he has held a faculty position since 2005. He earned his Ph.D. degree in 2000 from the University of British Columbia in Vancouver, Canada, where he studied the role of the MHC class I cytoplasmic tail in antigen cross-presentation and the generation of antiviral immune responses. He performed his postdoctoral studies under Dr. Steven Rosenberg at the Surgery Branch, National Institutes of Health in Bethesda, Maryland where he gained valuable experience in human tumor immunology with a clinical and translational focus. Dr. Lizee's research over the past 10 years has focused on identifying personalized and shared tumor antigens using genetic sequencing and mass spectrometry-based techniques leading to the development of novel antigen-specific immunotherapies, including neoantigen peptide vaccines and T cell receptor (TCR)-based therapies for cancer patients.